Aldeyra needs more Tranquility
A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Astra gets Wilson disease bonus
ALXN1840 could challenge older copper chelators, but gene therapies are coming.
Aldeyra eyes the future
A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
